Modern Plasma Fractionation
Tóm tắt
Từ khóa
Tài liệu tham khảo
WHO
CHMP: Guideline on epidemiological data on blood transmissible infections. For inclusion in the Guideline on the Scientific data requirements for a Plasma Master File. (EMEA/CPMP/BWP/3794/03). EMEA/CPMP/BWP/125/04, January 2005. http://www.emea.eu.int: European Medicine Agency, 2005.
Burgstaler, 2003, Current instrumentation for apheresis, 95
Burnouf, 2003, Residual cell content in plasma from 3 centrifugal apheresis procedures, Transfusion, 11, 1522, 10.1046/j.1537-2995.2003.00543.x
Sonntag, 1998, Complement activation during plasma production depends on the apheresis technique, Transfus Med, 8, 205, 10.1046/j.1365-3148.1998.00150.x
Burnouf, 2004, Assessment of complement activation during membrane-based plasmapheresis procedures, J Clin Apheresis, 19, 142, 10.1002/jca.20019
Cardigan, 2001, The effect of leukocyte depletion on the quality of fresh-frozen plasma, Br J Haematol, 114, 233, 10.1046/j.1365-2141.2001.02907.x
Dodd, 2004, Current safety of the blood supply in the United States, Int J Hematol, 80, 301, 10.1532/IJH97.04123
Burnouf, 2000, Reducing the risk of infection from plasma products: Specific preventative strategies, Blood Rev, 14, 94, 10.1054/blre.2000.0129
Farrugia, 2004, Guide for the assessment of clotting factor concentrates for the treatment of hemophilia, 55
Farrugia, 2004, Plasma for fractionation: Safety and quality issues, Haemophilia, 10, 334, 10.1111/j.1365-2516.2004.00911.x
Willkommen, 1999, Safety issues for plasma derivatives and benefit from NAT testing, Biologicals, 27, 325, 10.1006/biol.1999.0227
Anonymous, 2005
Swärd-Nilsson, 2006, Factors influencing Factor VIII activity in frozen plasma, Vox Sang, 90, 33, 10.1111/j.1423-0410.2005.00715.x
Cohn, 1946, Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids, J Am Chem Soc, 68, 459, 10.1021/ja01207a034
Kistler, 1962, Large-scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier, Vox Sang, 7, 414, 10.1111/j.1423-0410.1962.tb03274.x
Burnouf, 1991, Integration of chromatography with traditional plasma protein fractionation methods, Bioseparation, 1, 383
Burnouf, 2001, Affinity chromatography in the industrial purification of plasma proteins for therapeutic use, J Biochem Biophys Methods, 49, 575, 10.1016/S0165-022X(01)00221-4
Tabor, 1999, The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1, Transfusion, 39, 1160, 10.1046/j.1537-2995.1999.39111160.x
Kreil, 2004, West Nile virus: Recent experience with the model virus approach, Dev Biol (Basel), 118, 101
Yunoki, 2004, Heat sensitivity of a SARS-associated coronavirus introduced into plasma products, Vox Sang, 87, 302, 10.1111/j.1423-0410.2004.00577.x
Rabenau, 2005, SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation, Biologicals, 33, 95, 10.1016/j.biologicals.2005.01.003
WHO, 2003, 1
CPMP, 1996
Horowitz, 1985, Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations, Transfusion, 25, 516, 10.1046/j.1537-2995.1985.25686071422.x
Nowak, 1993, Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation, Dev Biol Stand, 81, 169
Ng, 1985, Pasteurization of antihemophilic factor and model virus inactivation studies, Thromb Res, 39, 439, 10.1016/0049-3848(85)90167-7
Dichtelmuller, 2002, Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulin solution, Biologicals, 30, 135, 10.1006/biol.2002.0332
Korneyeva, 2002, Enveloped virus inactivation by caprylate: A robust alternative to solvent-detergent treatment in plasma derived intermediates, Biologicals, 30, 153, 10.1006/biol.2002.0334
Burnouf, 2003, Nanofiltration of plasma-derived biopharmaceutical products, Haemophilia, 9, 24, 10.1046/j.1365-2516.2003.00701.x
Burnouf, 2005, Place of nanofiltration for assuring viral safety of biologicals, Curr Nanosci, 1, 189, 10.2174/157341305774642894
Foster, 2000, Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products, Vox Sang, 78, 86, 10.1046/j.1423-0410.2000.7820086.x
WHO
Flan, 2005, Evaluation de l'efficacité des procédés de purification des proteins plasmatiques à éliminer les agents transmissibles non conventionnels, Virologie, 9, S45
Foster, 2004, Removal of TSE agents from blood products, Vox Sang, 87, 7, 10.1111/j.1741-6892.2004.00444.x
Foster, 2004, Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII, Vox Sang, 86, 92, 10.1111/j.0042-9007.2004.00403.x
Burdick, 2006, Clearance of prions during plasma protein manufacture, Transfus Med Rev, 20, 57, 10.1016/j.tmrv.2005.08.005
Tateishi, 2001, Scrapie removal using Planova virus removal filters, Biologicals, 29, 17, 10.1006/biol.2001.0269
Burnouf, 1991, A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography, Vox Sang, 60, 8, 10.1111/j.1423-0410.1991.tb00864.x
Goudemand, 2006, Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A, Blood, 107, 46, 10.1182/blood-2005-04-1371
Burnouf-Radosevich, 1992, Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate, Vox Sang, 62, 1, 10.1111/j.1423-0410.1992.tb01159.x
Mazurier, 2004, In vitro study of a triple-secured von Willebrand factor concentrate, Vox Sang, 86, 100, 10.1111/j.0042-9007.2004.00398.x
Kasper, 2005, 1
Radosevich, 1997, Fibrin sealant: Scientific rationale, production methods, properties, and current clinical use, Vox Sang, 72, 133, 10.1046/j.1423-0410.1997.7230133.x
Pejaudier, 1987, Appraisal of the protein composition of prothrombin complex concentrates of different origins, Vox Sang, 52, 1, 10.1111/j.1423-0410.1987.tb02979.x
Burnouf, 1995, Chromatography in plasma fractionation: benefits and future trends, J Chromatogr B Biomed Appl, 664, 3, 10.1016/0378-4347(94)00532-A
Burnouf, 1989, Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography, Vox Sang, 57, 225, 10.1111/j.1423-0410.1989.tb00832.x
Burnouf-Radosevich, 1992, A therapeutic, highly purified factor XI concentrate from human plasma, Transfusion, 32, 861, 10.1046/j.1537-2995.1992.32993110761.x
Dickneite, 2002, The importance of factor XIII as a component of fibrin sealants, J Surg Res, 107, 186, 10.1006/jsre.2002.6495
Tomokiyo, 2003, Large-scale production and properties of human plasma-derived activated Factor VII concentrate, Vox Sang, 84, 54, 10.1046/j.1423-0410.2003.00247.x
Burnouf, 1987, Biochemical and biological properties of an alpha 1-antitrypsin concentrate, Vox Sang, 52, 291, 10.1111/j.1423-0410.1987.tb04895.x
Radosevich, 2003, Chromatographic purification and properties of a therapeutic human protein C concentrate, J Chromatogr B Analyt Technol Biomed Life Sci, 790, 199, 10.1016/S1570-0232(03)00091-6
Kasper, 2006, Registry of clotting factor concentrates, 1
Jourdain, 1997, Effects of inter-alpha-inhibitor in experimental endotoxic shock and disseminated intravascular coagulation, Am J Respir Crit Care Med, 156, 1825, 10.1164/ajrccm.156.6.9611100
Wu, 2004, Delayed administration of human inter-alpha inhibitor proteins reduces mortality in sepsis, Crit Care Med, 32, 1747, 10.1097/01.CCM.0000132903.14121.0E
Peitsch, 1989, A purification method for apolipoprotein A-I and A-II, Anal Biochem, 178, 301, 10.1016/0003-2697(89)90642-8
Kilpatrick, 1997, Isolation of human mannan binding lectin, serum amyloid P component and related factors from Cohn fraction III, Transfus Med, 7, 289, 10.1046/j.1365-3148.1997.d01-40.x
Orthner, 1995, Large-scale production and properties of immunoaffinity-purified human activated protein C concentrate, Vox Sang, 69, 309, 10.1111/j.1423-0410.1995.tb00366.x